Help Patients Overcome Hurdles With GLP-1 Agonists
February 2024
Rxs are rolling in for GLP-1 agonists...liraglutide (Victoza, etc), semaglutide (Ozempic, etc), dulaglutide (Trulicity), etc.
It’s partly because these injectable meds are a first-line option for type 2 diabetes in patients who also have certain medical conditions...such as heart or kidney disease.
Plus injectable semaglutide (Wegovy) or tirzepatide (Zepbound) seem to be the most effective Rxs for managing overweight or obesity.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote